Pfizer Inc.

- Pfizer is focused on deleveraging as rapidly as possible and has actively reduced $4.4 billion in debt year-to-date, with plans to continue. - The company is open to evaluating all options for capital deployment, including potential monetization of existing assets to support deleveraging and strategic objectives. - No specific new fundraising through debt or equity was mentioned, but Pfizer is considering business development opportunities and asset monetization. - The company is committed to balancing deleveraging with maintaining flexibility on the balance sheet to fund growth and investments. - No explicit plans for immediate new fundraising via debt or equity were disclosed during the Q3 2024 call.

- Pfizer continues to evaluate business development (BD) opportunities, including potential monetization of existing assets to support deleveraging and strategic growth. - Investments in mRNA infrastructure globally, particularly through the BioNTech partnership, are ongoing and considered transformational beyond revenue growth. - Commitment to advancing R&D pipeline with new scientific leadership and prioritization of projects, including significant oncology research following the Seagen acquisition. - Continued investment in next-generation vaccines and novel therapies, such as the 25-valent and >30-valent pneumococcal conjugate vaccines, indicating advanced technology development. - Execution of a $4 billion operational expenditure reduction plan to improve efficiency without hindering growth. - Preparing 2025 financial plans with acknowledgment of significant “pushes and pulls” affecting core and COVID-related businesses. - Focused on cost-efficient R&D and SG&A while maintaining innovation and pipeline advancement.

- Pfizer projects operational revenue growth (excluding COVID-19 products) of 9% to 11% in 2024. - COVID-19 product revenues expected at $10.5 billion ($5B COMIRNATY, $5.5B PAXLOVID). - ABRYSVO shows strong momentum with doubled market share in retail COVID vaccine shots, with volumes expected to continue in Q4. - International growth strong at 31%, with expanding reimbursements in 45 countries and potential to increase diagnosis rates. - Vinda (likely a pharmaceutical franchise) shows strong US growth but volume growth expected to slow in 2025 due to competitive entrants. - Seagen integration delivering $2.3 billion year-to-date revenue, with pipeline products showing blockbuster potential. - Obesity oral treatments advancing; Pfizer aims to be #2 in oral obesity drugs, highlighting large market potential. - Pipeline assets in cachexia and oncology indicate significant unmet needs and large market opportunities depending on trial outcomes. - Pfizer plans continued operational execution and business development to sustain growth and shareholder value.

- Pfizer raised its full-year 2024 total revenue guidance to a range of $61 billion to $64 billion, with operational revenue growth (excluding COVID-19 products) expected at 9% to 11%. - Adjusted diluted earnings per share (EPS) guidance increased to $2.75 to $2.95 for 2024, reflecting top-line growth and operational leverage. - Earnings per share guidance includes an anticipated $0.40 dilution from the Seagen acquisition financing costs. - The company aims to continue deleveraging rapidly by reducing debt and monetizing assets to support strategic priorities. - Strong pipeline performance and successful integration of acquisitions like Seagen are expected to drive significant shareholder value and operational leverage over time. - Pfizer expects ongoing margin expansion through cost reduction plans and operational efficiency, supporting enhanced profitability in coming years.

- For ABRYSVO (RSV vaccine): - Stocking efforts were made to have ABRYSVO available in fridges and retailers at the start of the season. - Q3 reflected appropriate stocking levels. - Administration volumes started in August and were lower than last year due to COVID vaccine timing and market changes. - Anticipate continued administration volumes into Q4. - Strong momentum in maternal vaccinations with a 20% uptake increase in September, doubling from last season. - Pediatric vaccinations are gaining reimbursements and positive recommendations internationally, with ongoing negotiations. - Overall, inventory and orderbook dynamics reflect proactive stocking, market shifts, and growth potential, especially heading into Q4 2024.